key: cord-0891340-1jj7ayd2
authors: Dhoot, Roshni; Kansal, Aman; Handran, Chauncy; Haykal, Tarek; Ronald, James; Kappus, Matthew; Arepally, Gowthami M.; Graham, Mark; Strouse, John J.
title: Thrombocytopenia and splanchnic thrombosis after Ad26.COV2.S vaccination successfully treated with transjugular intrahepatic portosystemic shunting and thrombectomy
date: 2021-06-14
journal: Am J Hematol
DOI: 10.1002/ajh.26258
sha: b8db360ec8c9af8d0fed181dab81f083de762917
doc_id: 891340
cord_uid: 1jj7ayd2

nan

F I G U R E 2 Post-TIPS coronal image from CT performed on Day 1 after TIPS showing normal appearing portal, SMV and splenic veins (black arrows) flowing into a patent TIPS (white arrow). The spleen enhanced normally (asterisk) and the appearance of the bowel was improved F I G U R E 1 Pre-TIPS coronal image from CT performed on Day 4 of hospitalization showing portal, SMV and splenic vein thrombosis (black arrows), bowel wall thickening (white arrows), and splenic hypoenhancement (asterisk) worse compared to the CT on admission Our patient, a 24-year-old previously healthy male, presented with 10-day history of severe abdominal pain, nausea, vomiting, and decreased oral intake. He had been seen at urgent care 2 days earlier for similar symptoms, treated for presumed gastritis with belladonna alkaloids, phenobarbital, antacid, and viscous lidocaine, and had moderate improvement. He received the Ad26.COV2.S vaccine 11 days prior to onset of symptoms.

He had diffuse abdominal tenderness and mild thrombocytopenia (66 Â 10 3 /μl), leukocytosis (11.4 Â 10 3 /μl), elevated D-dimer (>5250 ng/ml) with normal hemoglobin 13.8 g/dl. That evening, he had worsening abdominal pain, maroon-colored emesis and drop in hemoglobin to 7.9 g/dl. He was transferred to the intensive care unit.

Testing for SARS-CoV-2 was negative. Contrast enhanced computerized tomography (CT) showed extensive occlusive thrombosis of the portal, superior mesenteric (SMV), and splenic veins with severe bowel wall thickening concerning for venous ischemia. Brain magnetic resonance venography was negative for cerebral venous thrombosis.

He was treated with heparin for 20 h and then bivalirudin due to con- He was transferred to our institution for evaluation by interventional radiology. We administered intravenous immunoglobulin (IVIG) 1 g/kg on Days 5 and 6. After multidisciplinary discussion, we proceeded with transjugular intrahepatic portosystemic shunt (TIPS) 1 and thrombectomy to reduce the risk of further bowel ischemia and long-term complications of portal hypertension. 2 We used intravascular ultrasound guidance with intracardiac echocardiography (ICE-Boston Scientific) to gain access to the thrombosed portal venous system. We advanced, with some difficulty, a wire through the thrombosed portal vein and SMV into the IVIG. Her platelets recovered, though she was still critically ill at time of the report. 5 Clark et al. described a 40-year-old Caucasian female with thrombocytopenia, cerebral venous sinus thrombosis, and pulmonary embolism following Ad26.COV2.S vaccination. She was treated with bivalirudin and her platelets rapidly returned to normal. She was discharged on Day 6 with resolution of headache and no clinical sequelae of thromboses at the time of the report. 6 This case suggests that thrombectomy and TIPS can be safe and effective for severe VITT involving the splanchnic circulation. Additional studies are needed to establish the role of mechanical intervention in VITT, particularly in cases refractory to medical therapies.

This case also highlights that vaccine-induced thrombotic thrombocytopenia with life-threatening illness can also affect males. We are

The role of transjugular intrahepatic portosystemic shunt in the management of portal vein thrombosis

Portal vein thrombosis

Pretransplant portal vein recanalization-transjugular intrahepatic portosystemic shunt in patients with complete obliterative portal vein thrombosis

Liver transplant in patients with portal vein thrombosis: the experience of 55 patients

Thrombotic thrombocytopenia after Ad26.COV2.S vaccination

Early outcomes of bivalirudin therapy for thrombotic thrombocytopenia and cerebral venous sinus thrombosis after Ad26.COV2.S vaccination: a case report

not aware of any male deaths from VITT, but further studies are needed to establish gender differences.

The authors declare no conflict of interest.

https://orcid.org/0000-0001-9092-6998John J. Strouse https://orcid.org/0000-0003-0341-1457